phiC31 integrase in liver  
Stanford University  
line decor
    HOME  ::  
line decor

Selected Recent Publications
  •  Calos, M.P. (2016). The CRISPR way to think about Duchenne’s. New England Journal of Medicine 374, 1684-1686.[Article]

  •  Turan, S., Farruggio, A.P., Srifa, W., Day, J.W., and Calos, M.P. (2016). Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Molecular Therapy 24, 685-696.[Abstract]

  •  Calos, M.P. (2016). Phage integrases for genome editing. In Genome Editing: The Next Step in Gene Therapy. Eds. Cathomen, T., Hirsch, M., Porteus, M., ASGCT and Springer. Advances in Experimental Medicine and Biology 895, 81-91. [Chapter]

  •  Geisinger, J.M., Turan, S., Hernandez, S., Spector, L.P., and Calos, M.P. (2016). In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucleic Acids Research 44 (8): e76. [Abstract]

  •  Woodard, L.E. and Michele P. Calos (2015). Nonviral genome modification strategies for gene therapy: Transposon, integrase, and nuclease systems, Chapter 26, in Gene and Cell Therapy Therapeutic Mechanisms and Strategies, Fourth Edition, ed. Templeton, N.S., CRC Press, pp.675-700.

  •  Geisinger, J.M. and Calos, M.P. (2015). Using phage integrases in a site-specific dual integrase cassette exchange strategy. Methods Mol. Biol. 1239, 29-38. [Abstract]

  • Farruggio AF, Calos MF (2014) Serine integrase chimeras with activity in E.coli and HeLa cells. Biology Open 3 895-903.  [Abstract]

  • Zhao C, Farruggio AF, Bjornson CR, Chavez CL, Geisinger JM, Neal TL, Karow M Calos MF. (2014) Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One 9(4): e96279 [Abstract]

  •   Zhu, F., Gamboa, M., Farruggio, A.P., Hippenmeyer, S., Tasic, B., Schuele, B., Chen-Tsai, Y., and Calos, M.P. (2014). DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucleic Acids Research 42, e34.[Abstract]

  • Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Buren JA, Buschmann M, Byrne BJ, Calos M, et al. (2013) Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther. Feb 21(2):266-8.  [Abstract]
  • Geisinger, J.M. and Calos, M.P. (2012).  Site-specific recombination using phiC31 integrase.  In "Site-directed insertion of transgenes.", (P. Duchateau and S. Renault, eds.) Topics in Current Genetics 23, Springer, Chapter 8, 211-239. [Abstract]
  • Farruggio, A.P., Chavez, C.L., Mikell, C.L., and Calos, M.P. (2012).  Efficient reversal of phiC31 integrase recombination in mammalian cells.  Biotech. J., Biotechnol. J. 7, 1332 - 1336.[Abstract]
  • Lan, F., Liu, J., Narsinh, K., Hu, S., Han, L., Lee, A.S., Karow, M., Nguyen, P.K., Nag, D., Calos, M.P., Robbins, R.C., and Wu, J.C. (2012).  Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique.  Circulation 126 (suppl 1):S20 - S28. [Abstract]
  • Hillman RT, Calos MP. (2012) Site-specific integration with bacteriophage phiC31 integrase. Cold Spring Harb Protoc; May:2012 (5). [Abstract]
  • Chavez, C.L., Keravala, A., Chu, J.N., Farruggio, A.P., Gabrovsky, V.E., Voorberg, J., and Calos, M.P. (2012).  Long-term expression of human coagulation factor VIII in a tolerant mouse model using the phiC31 integrase system.  Human Gene Therapy 23, 390 - 398. [Abstract]
  • Keravala, A., Chavez, C.L., Hu, G., Woodard, L.E., Monahan, P.E., and Calos, M.P. (2011) Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy.  Gene Therapy 18, 842-848. [Abstract]
  • Karow, M. and Calos, M.P. (2011).  The therapeutic potential of phiC31 integrase as a gene therapy system.  Expert Opin. Biol. Ther. 11, 1287-1296. [Abstract]
  • Chavez, C.L. and Calos, M.P. (2011). Therapeutic applications of the phiC31 integrase system. Current Gene Therapy 11, 375 - 381.[Abstract]
  • Karow, M., Chavez, C.L., Farruggio, A.P., Geisinger, J.M., Keravala, A., Jung, W.E., Lan, F., Wu, J.C., Chen-Tsai, Y., and Calos, M.P. (2011) Site-specific recombinase strategy to create iPS cells efficiently with plasmid DNA.  Stem Cells 29, 1696 - 1704. [Abstract]

  • Ito, M., Yamanouchi, K., Naito, K., Calos, M.P. and Tojo, H. (2011). Site-specific integration of transgene targeting an endogenous lox-like site in early mouse embryos. J. Appl. Genet. 52, 89 -94. [Abstract]

  • Woodard LE, Keravala A, Jung WE, Wapinski OL, Yang Q, Felsher DW, Calos MP. (2010) Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS ONE 5(6): e11367. [Article]

  • Chavez CL, Keravala A, Woodard LE, Hillman RT, Stowe TR, Chu JN, Calos MP. (2010). Kinetics and longevity of φC31 integrase in mouse liver and cultured cells. Hum Gene Ther. 21(10):1287-97. [Abstract]

  • Woodard LE, Calos MP. (2010). DNA integrating vectors (transposon, integrase). In A Guide to Human Gene Therapy, Chapter 8, (R.W. Herzog and S. Zolotukhin, eds.) World Scientific, pp. 123 - 138.

  • Woodard LE, Hillman RT, Keravala A, Lee S, Calos MP. (2010). Effect of nuclear localization and hydrodynamic delivery-induced cell division on φC31 integrase activity. Gene Therapy 17, 217-226. [Abstract]

  • Jung WE. Calos MP. (2009). PhiC31 integrase for modification of stem cells. In Emerging Technology Platforms for Stem Cells, Chapter 20, (U. Lakshmipathy, J.D. Chesnut, and B. Thyagaragan, eds.) John Wiley and Sons, Inc.

  • Keravala A, Lee S, Thyagarajan B, Olivares EC, Gabrovsky VE, Woodard LE, Calos MP. (2009). Mutational derivatives of phiC31 integrase with increased efficiency and specificity. Mol Ther. 17(1):112-20. [Abstract]

  • Woodard LE, Calos MP. (2008). Nonviral genome modification strategies for gene therapy: Transposon, integrase, and homologous recombination systems. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 3rd Edition. (N.S. Templeton, ed.) Taylor & Francis Group, CRC Press, Boca Raton, FL. Chapter 31, 677-691.

  • Gabrovsky V, Calos MP. (2008). Factoring nonviral gene therapy into a cure for hemophilia A. Curr Opin Mol Ther. 10(5):464-70. [Abstract]

  • Keravala A, Ormerod BK, Palmer TD, Calos MP. (2008). Long-term transgene expression in mouse neural progenitor cells modified with φC31 integrase. J Neurosci Methods. 173(2):299-305. [Abstract]

  • Keravala A, Calos MP. (2008). Site-specific chromosomal integration mediated by φC31 integrase. Methods Mol Biol. 435:165-73. [Abstract]

  • Hillman RT, Calos MP. (2007). Site-specific integration with phage φC31 integrase. In Gene Transfer: Delivery and Expression of DNA and RNA, A Laboratory Manual. (T. Friedmann and J. Rossi, eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Chapter 65, 653 - 660.

  • Fish MP, Groth AC, Calos MP, Nusse R. (2007). Creating transgenic Drosophila by microinjecting the site-specific φC31 integrase mRNA and a transgene-containing donor plasmid. Nat Protoc. 2(10):2325-31. [Abstract]

  • Calos MP. (2007). The φC31 integrase system for gene therapy. Curr Gene Ther. 6(6):633-45. [Abstract]

  • Portlock JL, Keravala A, Bertoni C, Lee S, Rando TA, Calos MP. (2006). Long-term increase in mVEGF164 in mouse hindlimb muscle mediated by phage φC31 integrase after nonviral DNA delivery. Hum Gene Ther. 17(8):871-6. [Abstract]

  • Chalberg TW, Vankov A, Molnar FE, Butterwick AF, Huie P, Calos MP, Palanker DV. (2006). Gene transfer to rabbit retina with electron avalanche transfection. Invest Ophthalmol Vis Sci. 47(9):4083-90. [Abstract]

  • Keravala A, Portlock JL, Nash JA, Vitrant DG, Robbins PD, Calos MP. (2006). φC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints. J Gene Med. 8(8):1008-17. [Abstract]

  • Keravala A, Groth AC, Jarrahian S, Thyagarajan B, Hoyt JJ, Kirby PJ, Calos MP. (2006). A diversity of serine phage integrases mediate site-specific recombination in mammalian cells. Mol Genet Genomics. 276(2):135-46. [Abstract]

  • Ishikawa Y, Tanaka N, Murakami K, Uchiyama T, Kumaki S, Tsuchiya S, Kugoh H, Oshimura M, Calos MP, Sugamura K. (2006). Phage φC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J Gene Med. 8(5):646-53. [Abstract]

  • Chalberg TW, Portlock JL, Olivares EC, Thyagarajan B, Kirby PJ, Hillman RT, Hoelters J, Calos MP. (2006). Integration specificity of phage φC31 integrase in the human genome. J Mol Biol. 357(1):28-48. [Abstract]

  • Bertoni C, Jarrahian S, Wheeler TM, Li Y, Olivares EC, Calos MP, Rando TA. (2006). Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci U S A. 103(2):419-24. [Abstract]

  • Ginsburg DS, Calos MP. (2005). Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv Genet. 54:179-87. [Abstract]

  • Thyagarajan B, Calos MP. (2005). Site-specific integration for high-level protein production in mammalian cells. Methods Mol Biol. 308:99-106. [Abstract]

  • Ginsburg D, Thyagarajan B, Phillips JE, Calos MP. (2005). Gene delivery by viruses. In: Encyclopedia of Life Sciences. London: Nature Publishing Group. [Abstract]

  • Chalberg, T., Phillips, J.E and Calos, M.P. (2005). Transfection of DNA into mammalian cells in culture. In: Encyclopedia of Life Sciences. London: Nature Publishing Group. [Abstract]

  • Chalberg TW, Genise HL, Vollrath D, Calos MP. (2005). phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci. 46(6):2140-6. [Abstract]

  • Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M. (2005). In vivo correction of murine hereditary tyrosinemia type I by φC31 integrase-mediated gene delivery. Mol Ther. 11(3):399-408. [Abstract]

  • Quenneville SP, Chapdelaine P, Rousseau J, Beaulieu J, Caron NJ, Skuk D, Mills P, Olivares EC, Calos MP, Tremblay JP. (2004). Nucleofection of muscle-derived stem cells and myoblasts with φC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther. 10(4):679-87. [Abstract]

  • Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ. (2004). Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol. 78(12):6556-66. [Abstract]

  • Groth AC, Fish M, Nusse R, Calos MP. (2004). Construction of transgenic Drosophila by using the site-specific integrase from phage φC31. Genetics. 166(4):1775-82. [Abstract]

  • Groth AC, Calos MP. (2004). Phage integrases: biology and applications. J Mol Biol. 335(3):667-78. [Abstract]

  • Olivares EC, Calos MP. (2003). Phage φC31 integrase-mediated site-specific integration for gene therapy. Gene Therapy and Regulation 2, 103-120.

  • Stoll SM, Meuse L, Kay MA, Calos MP. (2003). Role of EBV and genomic sequences in gene expression from extrachromosomal gene therapy vectors in mouse liver. Gene Therapy and Molecular Biology 7, 211-219.

  • Hollis RP, Stoll SM, Sclimenti CR, Lin J, Chen-Tsai Y, Calos MP. (2003). Phage integrases for the construction and manipulation of transgenic mammals. Reprod Biol Endocrinol. 1:79. [Abstract]

  • Portlock JL, Calos MP. (2003). Site-specific genomic strategies for gene therapy. Curr Opin Mol Ther. 5(4):376-82. [Abstract]

  • Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA. (2003). φC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther. 14(9):923-8. [Abstract]

  • Sclimenti CR, Neviaser AS, Baba EJ, Meuse L, Kay MA, Calos MP. (2003). Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice. Biotechnol. Prog. 19, 144-151.

  • Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP. (2002). Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol. 20(11):1124-8. [Abstract]

  • Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat Med. 8(10):1166-70. [Abstract]

  • Stoll SM, Calos MP. (2002). Extrachromosomal plasmid vectors for gene therapy. Curr. Opinion Mol. Therapeutics 4, 299-305.

  • Stoll SM, Ginsburg DS, Calos MP. (2002). Phage TP901-1 site-specific integrase functions in human cells. J Bacteriol. 184(13):3657-63. [Abstract]

  • Sclimenti CR, Thyagarajan B, Calos MP. (2001). Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res. 29(24):5044-51. [Abstract]

  • Olivares EC, Hollis RP, Calos MP. (2001). Phage R4 integrase mediates site-specific integration in human cells. Gene. 278(1-2):167-76. [Abstract]

  • Stoll SM, Sclimenti CR, Baba EJ, Meuse L, Kay MA, Calos MP. (2001). Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol Ther. 4(2):122-9 [Abstract]

  • Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. (2001). Site-specific genomic integration in mammalian cells mediated by phage φC31 integrase. Mol Cell Biol. 21(12):3926-34. [Abstract]

  • Thyagarajan B, Phillips JE, Calos MP. (2001). Gene delivery by viruses. In: Encyclopedia of Life Sciences. London: Nature Publishing Group.

  • Sclimenti CR, Baba EJ, Calos MP. (2000). An extrachromosomal tetracycline-regulatable system for mammalian cells. Nucleic Acids Res. 28(17):E80. [Abstract]

  • Groth AC, Olivares EC, Thyagarajan B, Calos MP. (2000). A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci U S A. 97(11):5995-6000. [Abstract]

  • Thyagarajan B, Guimarães MJ, Groth AC, Calos MP. (2000). Mammalian genomes contain active recombinase recognition sites. Gene. 244(1-2):47-54. [Abstract]

Maintained by Todd Gallagher
Last updated on
February 17th, 2016